In the latest step to combat the epidemic of opioid abuse, U.S. officials urge generic drug makers to make changes to opioids.
Mainly supportive of guidelines, but concerns include a lack of evidence underlying some new recommendations.
A pharmacist-led comprehensive medication assessment showed a high prevalence of polypharmacy and inappropriate medication use among older patients with cancer.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
Prescribers of extended-release/long-acting opioid analgesics are encouraged to participate in continuing medical education provided by manufacturers of these analgesics.
Falsified and substandard medications pose public health problems around the world, and international action should be taken to combat the phenomenon.
To assist industry in developing new formulations of opioid drugs with abuse-deterrent properties.
One-third of outpatients with breast, prostate, colon/rectum, or lung cancer were receiving insufficient pain treatment, particularly minorities.
Nurses working in hospitals with basic electronic health records report fewer problems with patient safety and quality-related outcomes.
A survey completed by approximately 400 oncology nurses practicing in ambulatory settings indicated that 16.9% had had their skin or eyes exposed to the toxic drugs they deliver.
Palliative care interventions should be introduced at diagnosis as a part of disease management rather than not until the end of life, suggests a review of cancer pain management.
A method employing fluorescent detection appears to be more adept than conventional immunohistochemistry in identifying estrogen receptor (ER)-positive breast cancers.
Disruptions in supply impact patient care. Nurses should know when to use a substitution drug and when to wait for the next shipment.
Roxane Laboratories has made labeling and product-packaging changes to its morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) due to accidental overdoses that resulted in adverse events and deaths.
A tablet delivering transmucosal fentanyl, Abstral is indicated for the management of breakthrough pain in adult cancer patients who are already using opioids around the clock.
The advisor forum answers questions about drug screens, coping with chemo brain, anemia in patients with MDS, and more.
This article reviews current practices of opioid prescribing in palliative care and suggests some pointers for safe prescribing for these patients.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|